Syndax Pharmaceuticals Inc.

These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.

Snap judgments lead to bad decisions and bad decisions lead to big losses, Cramer says.

Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.

The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.

These are just a few of the names I expect to do well to close out 2018.

These are a few of the names I expect to do well to close out 2018.

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

These names are moving up or down in a big way ahead of releasing drug-trial results.

Speculative action is keeping sentiment from being more negative.

The biotech sector has seen a big rally, but there are still opportunities.

Two members of Mark Zuckerberg's AI team unveiled big plans in an email chain

These compact and midsized sport utility vehicles earned CR’s highest marks—and sell for wallet-friendly prices.

The video game company has announced a highly anticipated product amid low sales.